No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC

The phase 3 CAUREL trial evaluating the combination of an anti-PD-L1 and an EGFR-TKI in advanced EGFR-mutant NSCLC was terminated early because of safety concerns from a related trial.

from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2SPPn7m